SEC Form 4 · accession 0001209191-17-046027
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 110,624 | $45.11 | A | 400,266 | D | |
| Common Stock | Jul 19, 2017 | M | 73,750 | $48.74 | A | 474,016 | D | |
| Common Stock | Jul 19, 2017 | S | 184,374 | $161.00 | D | 289,642 | D | |
| Common StockF2,F3 | Jul 21, 2017 | S | 700 | $157.42 | D | 288,942 | D | |
| Common StockF3,F4 | Jul 21, 2017 | S | 4,837 | $158.46 | D | 284,105 | D | |
| Common StockF3,F5 | Jul 21, 2017 | S | 3,500 | $159.34 | D | 280,605 | D | |
| Common StockF3,F6 | Jul 21, 2017 | S | 900 | $160.42 | D | 279,705 | D | |
| Common StockF3,F7 | Jul 21, 2017 | S | 17,255 | $161.43 | D | 262,450 | D | |
| Common StockF3,F8 | Jul 21, 2017 | S | 5,058 | $162.08 | D | 257,392 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $45.11 | Jul 19, 2017 | M | 110,624 | D | — | Feb 4, 2023 | Common Stock | 110,624 | 66,376 | D |
| Stock Option (Right to Buy)F9 | $48.74 | Jul 19, 2017 | M | 73,750 | D | — | Jul 24, 2022 | Common Stock | 73,750 | 44,250 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $157.42 (range $156.81 to $157.71).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $158.46 (range $157.88 to $158.86).
- F5Open market sales reported on this line occurred at a weighted average price of $159.34 (range $158.89 to $159.77).
- F6Open market sales reported on this line occurred at a weighted average price of $160.42 (range $159.90 to $160.86).
- F7Open market sales reported on this line occurred at a weighted average price of $161.43 (range $160.92 to $161.91).
- F8Open market sales reported on this line occurred at a weighted average price of $162.08 (range $161.92 to $162.45).
- F9Fully vested.